Use of pimecrolimus cream 1% (Elidel®) in the treatment of atopic dermatitis in infants and children: The effects of ethnic origin and baseline disease severity on treatment outcome

International Journal of Dermatology

Volumn 44, Issue 1, 2005, Pages 70-75

  Eichenfield, Lawrence F ^{a,b,c,d,e,f,g,h,i}   Lucky, Anne W ^{a,b,c,d,e,f,g,h}   Langley, Richard G B ^{a,b,c,d,e,f,g,h}   Lynde, Charles ^{a,b,c,d,e,f,g,h}   Kaufmann, Roland ^{a,b,c,d,e,f,g,h}   Todd, Gail ^{a,b,c,d,e,f,g,h}   Lindsley, Linda ^{a,b,c,d,e,f,g,h}   Barbier, Nathalie ^{a,b,c,d,e,f,g,h}   Felser, James M ^{a,b,c,d,e,f,g,h}  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Dermatology Research Associates   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f GOETHE UNIVERSITY   (Germany)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ Novartis Pharma AG ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DRUG VEHICLE; PIMECROLIMUS;

ADOLESCENT; AFRICAN AMERICAN; ARTICLE; ASIAN; ATOPIC DERMATITIS; BURNING SENSATION; CAUCASIAN; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG USE; ECZEMA; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC DISEASE; TREATMENT OUTCOME;

ADOLESCENT; AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN AMERICANS; CALCINEURIN; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HISPANIC AMERICANS; HUMANS; INFANT; PEPTIDYLPROLYL ISOMERASE; SAFETY; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; VEHICLES;

EID: 13444311052     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02234.x     Document Type: Article

References (18)

1. Bernard LA, Eichenfield LF. Topical immunomodulators for atopic dermatitis. Curr Opin Pediatr 2002; 14: 414-418.
2. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002; 62: 817-840.
3. Ho VC, Gupta AK, Kaufmann R, et al. Safety and efficacy of nonsteroid, pimecrolimus cream 1%, in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155-162.
4. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504.
5. Williams HC, Pembroke AC, Forsdyke H, et al. London-born black Caribbean children are at increased risk of atopic dermatitis. J Am Acad Dermatol 1995; 32: 212-217.
6. Schachner L, Ling NS, Press S. A statistical analysis of a pediatric dermatology clinic. Pediatr Dermatol 1983; 1: 157-164.
7. Davis LR, Martin, RH, Sarkany I. Atopic eczema in European and negro West Indian infants in London. Br J Dermatol 1961; 73 410-414.
8. Janumpally SR, Feldman SR, Gupta AK, Fleischer AB Jr. In the United States, blacks and Asian/Pacific Islanders are more likely than whites to seek medical care for atopic dermatitis. Arch Dermatol 2002; 138: 634-637.
9. Finlay AY. Measurement of disease activity and outcome in atopic dermatitis. Br J Dermatol 1996; 135: 509-515.
10. Charman C, Williams H. Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000; 136: 763-769.
11. Williams HC, Burney PG, Hay RJ, et al. The UK Working Party's diagnostic criteria for atopic dermatitis. Br J Dermatol 1994; 131: 383-396.
12. Hanifin JM, Thurston MS, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
14. Wood AJ. Racial differences in the response to drugs - pointers to genetic differences. N Engl J Med 2001; 344: 1394-1396.
15. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264-273.
16. Meingassner J, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137: 568-576.
17. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20: 233-241.
18. Van Leent EJ, Ebelin ME, Burtin P, et al. Low systemic exposure after repeated topical application of Pimecrolimus (Elidel, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002; 204: 63-68.